Petosemtamab for squamous cell carcinoma of head and neck

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 3 trial. Large late-stage trial in people. As of 19 Nov 2026, from 3 registered trials.

Why this status

  1. 25 Jun 2024: Trial started, NCT06496178
  2. 11 Jul 2024: Trial registered, NCT06496178
  3. 29 Jul 2024: Trial registered, NCT06525220
  4. 25 Sep 2024: Trial started, NCT06525220

The trials

NCT03526835: A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors

State
Under way
Phase
Phase 1 and Phase 2
People
560 planned
Started
2 May 2018
Primary completion
May 2028
Arms
MCLA-158 (Single-Agent), MCLA-158 + Pembrolizumab, MCLA-158 + FOLFIRI combination chemotherapy, MCLA-158 + FOLFOX combination chemotherapy
Results
None posted
  1. 2 May 2018: Trial started
  2. 16 May 2018: Trial registered

NCT06496178: A Phase 3 Study to Evaluate Petosemtamab Compared With Investigator's Choice Monotherapy in Previously Treated Head and Neck Squamous Cell Carcinoma Patients (LiGeR-HN2)

State
Under way
Phase
Phase 3
People
621 taking part
Started
25 Jun 2024
Primary completion
Feb 2028
Arms
MCLA-158
Results
None posted
  1. 25 Jun 2024: Trial started
  2. 11 Jul 2024: Trial registered

NCT06525220: A Phase 3 Study to Evaluate Petosemtamab Plus Pembrolizumab vs Pembrolizumab in First-line Treatment of Head and Neck Cancer (LiGeR - HN1)

State
Under way
Phase
Phase 3
People
699 taking part
Started
25 Sep 2024
Primary completion
Jan 2028
Arms
Petosemtamab + Pembrolizumab
Results
None posted
  1. 29 Jul 2024: Trial registered
  2. 25 Sep 2024: Trial started

How the status changed

  1. 19 Nov 2026: First set: Phase 3 trial

About the treatment

Also known as MCLA-158 + FOLFIRI, MCLA-158 + FOLFOX, MCLA-158 + Pembrolizumab.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.